Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954728 · ClinicalTrials.gov registry record · NA
Cognitive-behavioral Therapy vs. Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder
A NA study of Avoidant/Restrictive Food Intake Disorder (ARFID), sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05954728: Active NA study of Avoidant/Restrictive Food Intake Disorder (ARFID), sponsored by Massachusetts General Hospital.
NCT05954728 is a NA study of Avoidant/Restrictive Food Intake Disorder (ARFID) that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05954728, a NA study of Avoidant/Restrictive Food Intake Disorder (ARFID), is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized controlledlinical trial, assessing the efficacy of cognitive- behavioral therapy (CBT-AR) and nutrition counseling for avoidant/restrictive food intake disorder (ARFID) for children and adolescents (ages 10-18 years).
Primary Outcome
Validated 6-item version of the Food Neophobia Scale used to assess food neophobia on a scale from 1 to 7, with higher scores indicating higher levels of food neophobia. The lowest score possible is 7, indicating low food neophobia, and highest score possible is 42, indicating high food neophobia.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
- BEHAVIORAL Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder
Study Locations (1)
Massachusetts
- Eating Disorders Clinical and Research Program - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What the registry record for NCT05954728 still lists
NCT05954728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Avoidant/Restrictive Food Intake Disorder (ARFID) appearing as the primary indexed condition, and to 2 interventions - of which Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR) is the first listed.
NCT05954728 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05954728 about?
NCT05954728 is a clinical study titled "Cognitive-behavioral Therapy vs. Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder". This study is a randomized controlledlinical trial, assessing the efficacy of cognitive- behavioral therapy (CBT-AR) and nutrition counseling for avoidant/restrictive food intake disorder (ARFID) for children and adolescents (ages 10-18 years).
What is the current status of trial NCT05954728?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-01-31. Estimated completion is 2026-03-31.
What conditions does trial NCT05954728 study?
This clinical trial studies the following conditions: Avoidant/Restrictive Food Intake Disorder (ARFID).
What interventions are being tested in trial NCT05954728?
The interventions under investigation include: Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR) (BEHAVIORAL), Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder (BEHAVIORAL).
Who is sponsoring clinical trial NCT05954728?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05954728 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05954728's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI